focus pipelin deliveri
april five compani coverag report result focu
less number pipelin regulatori commerci
updat shield key focu nda file feraccru come
month readout head-to-head studi versu lead iv iron drug
ferinject hansa medic result line
expect focu remain six-month follow data two
key trial kidney transplant hansa remain key pick us ahead
event molecular partner good progress proprietari
oncolog multi-darpin pipelin abicipar data readout remain
key catalyst btg report in-lin trade updat detail behind earli
stage asset materi impact share price albeit larg recov
sinclair pharma result pre-report last month key remain
question us partner deal silhouett instalift sinclair
announc lead commerci activ without partner
regulatori level cureti announc earli april long-anticip de novo fda
clearanc unyvero lrt system first-in-class molecular diagnost platform
direct competit focu shift us commerci execut
initi two new compani acacia pharma siemen healthin
acacia pharma develop stage pharma compani lead asset baremsi
anti-emet rescu set fda decis due oct siemen healthin
larg cap european play healthcar imag diagnost lead
posit within three busi segment
north american colleagu note fda commit streamlin
acceler approv gener note number updat read-across
name posit outlook hospit capital-expenditure move toward value-
base healthcar reson siemen healthin long-term strategi vision
wilson kol insight retin space duchenn muscular dystrophi
atop dermat car-t therapi
takeaway find document
takeaway month page
model review forecast chang page
month ahead trade idea page
versu consensu upcom result page
newsflow north america page
eu investor need know page
takeaway month eu healthcar research
april number result coverag less surpris
number focu month regulatori updat pipelin
progress earli april btg issu mix trade updat strong mid-teen cer
growth establish im asset ekoson io weaker sale early-stag
asset pneumrx coil whilst licens divis
help maintain growth rate see medium-term risk due gener
competitor product launch saw neg share price reaction day
time albeit share larg recov
shield hansa medic announc result
respect case number less relev sinc key focu
either compani clinic develop upcom trial result interact
regul shield next key event nda submiss subset
analysi ckd trial readout head-to-head studi versu
ferinject expect hansa medic key event stori
readout six-month follow-up data anticip ahead
complet deep dive clinic paper ascertain good data would
earli april cureti announc long-anticip de novo fda clearanc
unyvero lrt system first-in-class molecular diagnost platform direct
competit ce mark upcom launch unyvero uti cartridg
diagnosi urinari tract infect see posit step forward
broaden portfolio think requir demonstr clinic util
hospit ensur place system turn revenue-gener unit
molecular partner announc two updat proprietari oncolog asset
compani enter collabor astrazeneca on-going phase trial
tagrisso non-smal cell lung cancer nsclc bring
board azn top partner lower overal develop cost also open
potenti futur in-licens azn view addit moln present
addit patient data on-going phase studi relaps refractori multipl
myeloma rrmm reiter posit view trial half patient
show respons low dose cohort ii durat respons seem long
iii drug safe well toler
mereo biopharma report propos us ipo pull basi
market condit conduc offer whilst setback
compani see signific valu mereo sinc two orphan drug set read
proof concept data next two year one prime design
eu two asset blockbust potenti set enter phase
phase respect like
initi two new compani acacia pharma siemen healthin
acacia pharma clinic stage pharma compani focus post-op
nausea vomit ponv chemotherapy-induc nausea vomit cinv
market lead asset seek us approv year compani recent list
euronext rais model combin peak sale risk-
adjust dcf peer ev/sal valuat result pt siemen
healthin larg cap european diagnost imag player recent
debut frankfurt stock exchang see imag advanc
therapi segment continu outgrow market gener sector-lead
margin main upsid opportun lie diagnost turnaround
launch new atellica platform driver top line growth margin
improv deriv price target combin pe ev/ebitda
dcf all-in potenti return assign sector perform rate
highlight eu healthcar research
taken deep dive peer review public kidney transplant
kt ahead upcom trial result assess good data would look
like data avail far know enzym effect
turn highli sensitis un-transplant patient transplant one
key remain question follow-up data overal graft
review think clear step forward current techniqu
look graft success averag graft loss patient level
around base patient sampl base patient sampl
deceas live donor suggest failur far
seen one highli sensitis patient deceas live
donor refractori current techniqu exhaust treatment
option help transplant patient
exhibit graft loss averag deceas live donor kidney transplant recipi sensit
deceas live donor current data ide
sensit level current data ide
multipl public avail request capit market estim
data read posit believ hansa file earli acceler
current assumpt case expect updat
decis bla accept think earli submiss mean
narrow focus label also benchmark price dialysi
lead ultim higher peak sale volum off-set smaller
price increas event fda request data launch delay till
broader label lower price although model alreadi
align outcom model price late launch think stock
would react neg news
see meaning opportun beyond kt organ transplant
multipl autoimmun oncolog indic wait key risk safeti
approv progress think manag cognis risk
go broad fast product ahead approv
live donordeceas live donor deceas donor graft loss sub loss averag
cure fda approv unyvero system lrt cartridg
cureti receiv de novo clearanc us fda market unyvero
lower respiratori tract infect lrt applic cartridg us
first-in-class molecular test approv lower respiratori tract infect direct
mdx competit news materi posit compani share
alreadi respond well sinc turn year like posit news
view trade updat mix spite line perform top
line whilst establish im asset ekoson io asset deliv mid-teen cer
growth note perform early-stag asset pneumrx coil weak still
soon turn posit varithena licens pharma product still help
maintain growth rate mid-single-digit growth cer see medium-term
risk due competitor product launch genericis overal whilst
see qualiti btg specif io ekoson asset support long-term
growth plu strong balanc sheet support acquisit think disappoint
sale growth earlier-stag im asset risk establish brand could see
revenu profit growth stall
sann news omigapil earli stage
santhera report phase trial omigapil children adolesc
congenit muscular dystrophi show safe well toler callisto
phase trial test omigapil patient congenit muscular dystrophi
per protocol patient receiv omigapil daili liquid oral formul
dose rang mg/kg mg/kg bodi weight five dose ascend cohort
treatment dose level safe well toler result
encourag posit outcom develop omigapil
note asset still earli stage need see data first sign
efficaci abl make assess opportun potenti
part base case pt remain unchang
stx push ahead nda submiss feraccru
shield issu updat post pre-nda meet fda post
result present data subset analysi take news
materi posit compani albeit still hurdl investor consid
could lengthi review period rel submiss ii fda
could still ask anoth trial believ data insuffici iii label
consider given review subset analysi iv even approv base
upon data provid previous still think compani could conduct post-
approv phase market trial provid addit market data like fund
partnership point
run consider nuanc key event data ide
kidney transplant kt review paper benchmark result knock-on
consider launch timelin label model assumpt see
alreadi demonstr market lead benefit current treatment option
remain bullish within kt reiter op spec risk rate
stx result focu remain feraccru develop
result today larg expect revenu light
target expect european launch go slow focu remain
develop out-licens feraccru truth think number today
second fiddl recent event occur post year-end primarili ckd studi
failur meet origin primari endpoint manag revisit
data see stat sig result split specif patient manag
guid file nda see key event
rejuven share top compani expect read top line
result head-to-head studi feraccru versu lead iv iron product
ferinject also act catalyst share posit
provid runway end appear tight manag
guid sign out-licens contract feraccru gener up-front
cash push cash runway hope outcom nda
approv remain optimist compani salvag someth
us ckd studi importantli patent life asset believ
compani worth mcap current trade
moln collabor astrazeneca highlight valu potenti
molecular partner enter collabor azn on-going phase
trial moln lead proprietari asset tagrisso azn approv asset
egfr non-smal cell lung cancer nsclc current sale
agreement azn suppli tagrisso requir phase clinic trial plan
enrol pt save moln cash expens also provid potenti
futur benefit view see strateg valu develop nsclc azn
top partner potenti futur in-licens azn efficaci safeti shown
mileston royalti moln like lower develop cost overal
view combin also make lot sens biolog commerci
standpoint go nsclc egfr posit tumour high unmet need
littl competit block three escap pathway tumour relaps
current treatment data suggest rational approach
drug avastin tarceva
acph bb initi op spec risk spoon sugar
initi acacia pharma outperform spec risk pt acacia pharma
development-stag pharma compani repurpos amisulprid product
ponv cinv develop believ could arguabl best dopamin
antagonist product avail approv fda octob ponv cinv
expect see combin peak sale like risk-adjust
valuat base risk-adjust dcf peer-bas ev/sal provid pt
cure broaden eu portfolio
cureti announc ce-mark upcom launch unyvero uti
cartridg diagnosi sever urinari tract infect uti think ce-mark
clearanc launch unyvero uti cartridg posit step forward cureti
appli fast rel standard care microbiolog cell cultur sample-to-
answer unyvero technolog sever complic uti key sourc potenti
sever complic hospitalis patient time manag continu
broaden rang assay unyvero devic think requir
demonstr clinic util hospit ensur place system turn revenue-
indv track sublocad canada potenti revenu upsid model
indivior file new drug submiss nd health canada drug
director sublocad treatment moder sever opioid use disord
oud come back health canada grant prioriti review statu
sublocad april posit mean decis approv
come next six month ii regul see high unmet need
iii regul also recognis sublocad potenti yield
improv efficaci enhanc adher due monthli administr
histor work canadian market worth us market
potenti peak sale certainli posit name
approv model minim row revenu sublocad
could repres sourc upsid forecast assumpt approv
moln addit posit data on-going phase trial multipl
molecular partner present updat preliminari result on-going phase
studi bortezomib dexamethason patient relaps
refractori multipl myeloma rrmm european myeloma network meet
turin data present weekend includ efficaci data one
patient last patient low-dos cohort also achiev partial respons
bring total number patient reach partial respons one patient
reach good partial respons think data promis given
lowest dose test mg/kg yet half patient show
respons ii drug well toler advers event manag
consist vegf inhibitor henc addit safeti issu seen multi-
darpin wait addit data end year second cohort
higher dose mg/kg current on-going see higher dose well
toler lead greater respons rate
hmed ss surpris result key inflect point approach
hansa result see spend come slightli lower
expect suggest headroom full year forecast
invest case remain kidney transplant anti-gbm data read out
remain track hansa remain key pick us given valu see
immune-modul platform technolog clear upcom catalyst valid
view reiter op spec risk rate
shl gr good health regular check up advis diagnost initi sp
siemen healthin rare larg cap european pure-play healthcar imag
diagnost imag advanc therapi appear set continu outgrow
market gener sector-lead margin main upsid opportun lie
diagnost turnaround launch new atellica platform driver top
line growth margin improv use combin pe ev/ebitda dcf
weight see pe primari valuat metric investor use
arriv price target healthin all-in potenti return
mereo announc propos us ipo pull manag
suggest market condit conduc offer point time
even though mereo short-term need cash given balanc
sheet end-decemb see potenti neg compani may
need re-assess develop plan potenti formul plan asset
could instanc includ speed out-licens asset respiratori
drug even hh whilst one could argu compani
morphosi recent done us ipo would point
differ stage life cycl setback frustrat still see signific
valu compani ahead current share price stand particularli light
recent posit data read hh asset first class
chosen indic diversifi risk profil differ class/ differ
mechan action
sph ln under-valued investor like wait deliveri
finish in-lin expect detail today result lead
ebitda downgrad sinclair launch instalift direct us take
cautiou approach exu sale reset clock unlik garner investor
interest particularli given balanc sheet posit see merit
manag action see share fundament under-valued
model review forecast chang
interim result make forecast adjust reflect continu
growth top line off-set slight currenc headwind alongsid increment
invest sg sustain top line growth gross margin assumpt come
slightli driven currenc larger movement ebitda driven time
depreci charg new facil remind includ share base
payment ebit ebitda line pbt ep like consensu
would take ebit ebtida margin
exhibit summari forecast chang
move valuat model year appli revenu assumpt
similar multipl high valu tool player
add cash per share provid pt
top end consensu revenu expect forecast year also see
probabl upgrad high underli basi manag make
acquisit leverag platform
year june newchang newchang newchang margin margin margin exhibit summari peer valuat
valu factset includ abcam price may
year june cash non-cash work cash associ flow cash discontinu share net sheet year june plant non current current long term current deficit calendar compani newsflownih budget fund compani newsflowpotenti acquisitionsresult exhibit group financi estim
year june cash non-cash work cash associ flow cash discontinu share net sheet year june plant non current current long term current deficit calendar compani newsflownih budget fund compani newsflowpotenti acquisitionsresult
trade updat review recent result partner
make forecast adjust slower expect uptak repneu slower
ramp varithena headwind currenc assum usd rate
note spot rate provid headroom
estim offset view better outlook ekoson stellar
revenu number partner asset zytiga although net effect
revenu line downgrad bigger impact profit
anticip spend sg remain broadli constant
exhibit summari forecast chang
continu see balanc invest case btg posit view
long-term potenti intervent medicin divis off-set risk earli stage
asset varithena repneu key pharma asset crofab upcom
competit profit remain broadli flat forecast period us
zytiga revenu drop patent cliff approach think key variabl
manag deploy capit balanc sheet remain healthi
sotp model primarili dcf/rnpv franchis use wacc launch
asset termin growth rate depend franchis provid
pt previous support sector perform rate
exhibit summari btg sotp valuat
year march newchang newchang newchang margin margin margin valuationmethodologyrisk adjustmentmp/shun-risk un-risk p/sh downsid downsid p/sh old p/shchangenotecrofabdcfapprov bioclon asset gain greater tractiondigifabdcfapprov approv back cospeci pharmaceuticaldcf rnpv currenc drivenintervent oncologyrnpv current revenu run rate eu/usrepneu eudcfapprov usrnpv eu us approv expect reimburs dcfapprov given code dr willing utiliseintervent medicinedcf rnpv off-set move dcf yearzytigadcfapprov remain central exhibit summari product forecast chang
licens exhibit summari product forecast chang
productind product infoyear march revenu guidanc crotalina digoxin pois methotrex hand back -- gross vascularpharmacomechan cathet blood oncologychemo radio bead plu galil medic cancer emphysema sclerotherapoy venou diseas varicos consensu cancer exhibit group financi estim
incom statement year march rate rate rate rate margin cost margin margin acquir normalis held profit incom report fd normalis continu fd number group share fd year march debt ebitda debt per share yield work per exhibit group financi estim
year march cash non-cash work cash associ flow cash discontinu share net sheet year march plant non current current long term current deficit newsflow calendar newsflowproduct newsflowproduct read stop theraspher read epoch repneu studi read outgeograph expansionbiocompat biodegrad panel hear like
healthcar valuat tabl sector perform chart
price market close bst may gmt
capit market estim factset price inform denot act broker note siemen healthin list march henc ep avail
companyrecupsideptpricemcapevforecast growthforecast growthforecast compound-annual-growth-rate compound-annual-growth-rate compound-annual-growth-rate pharmaoutperform spec spec spec medic aboutperform spec seknanananananananananananahorizon discoverysector perform spec biopharma outperform spec partnersoutperform spec spec therapeuticsoutperform spec healthineerssector exclud cureti salesev ebitdap eu healthcar
exhibit weight averag share price perform coverag versu ftse share
jan april
jan april
jan april
jan april
jan april
jan april
share exhibit coverag perform versu peer wider sector
jan april
jan april
jan april
medicalnmc dechra pharmaceuticalsindivioreco anim groupabcamudg careianc pharmacv groupgenuscaretech holdingsclinigen groupconsort medicalsmith nephewfts sharestoxx europ eastrazenecamorphosysglaxosmithklinemolecular partnersbtgshirecambian grouphorizon discoveri grouphikma pharmaceuticalsvectura groupspir care gp sinclair pharmabenchmark holdingscircassia medicalnmc dechra pharmaceuticalsindiviori pharmaabcameco anim groupcaretech holdingsgenusudg caremorphosysclinigen groupcv groupcambian groupfts sharesmith nephewastrazenecahorizon discoveri groupglaxosmithklinestoxx europ econsort medicalbtgshiremolecular partnersspir care gp curetishikma pharmaceuticalsbenchmark holdingsvectura groupsinclair pharmacircassia hansa medicaldechra pharmaceuticalsi pharmamorphosysabcamindiviorgenusudg carecambian groupcaretech holdingsclinigen groupmereo biopharma groupbtgastrazenecaeco anim groupsmith nephewconsort medicalmolecular partnersstoxx europ efts sharehorizon discoveri groupcircassia pharm glaxosmithklineconvatec groupcv groupcuretisshirehikma pharmaceuticalsspir care gp benchmark holdingsvectura groupsinclair pharmavernalisshield month ahead trade idea
look may result convatec indivior
siemen healthin well horizon discoveri btg result
indivior result look updat perform film
franchis us row particular potenti market share movement ii
updat sublocad launch iii updat doj litig
recent also notic file new drug submiss nd
canada drug director sublocad see upon approv
commerci launch upsid potenti row revenu see sparc given
health canada grant prioriti review statu see approv like would
look updat potenti timelin approv subsequ launch
last week indivior share price strong run reach all-tim
high april level see short term risk indivior disappoint
roll sublocad long term view think fundament
indivior remain strong
result convatec issu guidanc refer worst
organ growth rate exclud cc product rationalis lowest
ever ebit margin sinc compani stand alon entiti frame
recent thesi upgrad outperform guidanc achiev even
beatabl see recent note execut critic opportun exist
look detail growth trajectori four divis
think strong would pave way good turn
provid reason clariti outlook division level model high
singl digit growth awc ostomi driven currenc pipelin launch
doubl digit growth cc driven recent woodburi acquisit low doubl
digit growth id basi strong volum growth
last week convatec share price rebound level
suggest minim upsid pt howev share still
cheap rel peer upsid estim possibl given conserv
guidanc see upsid possibl posit share result
healthin result anticip continu solid perform
imag advanc therapi term top line growth adjust profit
margin expect imag see broadli similar y-o-i organ revenu growth
diagnost still see ramp cost atellica solut roll-out
remain margin declin y-o-i howev see
pickup organ sale growth disappoint level
advanc therapi expect temper growth margin
strong perform forecast revenu growth margin come
growth top end guidanc respect
group model organ growth adjust profit margin despit
anticip fx headwind
key question earn call updat atellica solut roll-out
term recent placement convers instal base competit win
visibl potenti placement remaind year ii updat
turnaround ultrasound light mid-teen growth rate post peer
debut frankfurt stock exchang march siemen healthin
share price strong run went earli april level back
go result think share look fair valu unless
manag provid posit updat diagnost turnaround
result look comment priorit activ
proce recent rais ii progress commerci launch prepar
timelin find ex-u commerci partner iii feedback fda
regulatori fill iv updat partner discuss
on-going patent litig
also look clinic updat proprietari asset addit safeti
efficaci l-mind studi relapse/refractori dlbcl ii updat
sc formul progress phase studi design iii non-small-cel
lung cancer studi design iv updat public
data studi complet
whilst forecast quarterli expect total revenu quarter lower
given termin novarti collabor albeit expect slightli
off-set tremfya royalti yet updat estim us list
materi benefit morphosi cash posit
key question horizon discoveri result relat detail
division perform ii progress integr dharmacon iii detail
cash posit iv outlook
trade statement februari saw revenu go
line expect report growth suggest vs
forecast ebitda go break-even therefor break-even push
back concern cash posit year end versu
forecast would need clarif discrep
two month horizon discoveri share price materi
under-perform hesit buy ahead result spite discount
fair valu target price outstand question market appetit risk
asset low worri share could under-perform
issu result
term reimburs
follow trade updat detail look detail
updat division perform ii thought potenti off-set risk
crofab zytiga slower anticip growth early-stag asset iii
guidanc cautiou head result given could
opportun manag provid updat guidanc crofab particular
could act neg catalyst share forecast broadli in-lin
consensu begin come meaning albeit
think could off-set acquisit
earli april btg issu trade updat interpret mix
term perform establish versu early-stag asset sight line
perform top line see sparc brief recap note establish
im asset ekoson io asset deliv top line growth mid-teen
cer wherea btg record lower sale early-stag asset pneumrx coil cite
eu
pharmaceut divis report strong perform crofab voraxaz
key concern competit crofab due upcom launch bioclon
anavip end licens deliv singl digit cer growth
driven strong perform zytiga consciou recent newsflow
patent rule gener begin launch us next
month see note zytiga risk crystallis year caution
potenti catalyst timet coverag coverag peer
exhibit potenti catalyst timet coverag coverag peer
note indic project result releas date compani inform factset estim
stockmayjunejulyabcam result may biorad result may trade updat tbc acacia pharmateva result may result may heron result may biom result may integra lifesci result may tbc result result may medic system result tbc circassiaazn result may result juli result may trade updat tbc consort medicallonza result may consort ye trade updat result tbc gerresheim result juli aptar result tbc recipharm result tbc convatec convatec result may coloplast result may smith nephew result may result may result tbc curetisqiagen result may financi may result may phibro result may trade updat tbc eli lilli result juli vetoquinol result juli medicalhorizon discoveri result may biorad result may horizon discoveri result may result may camuru result may result tbc molecular partnersgilead may societi clinic oncolog june result tbc morphosysiniti phase atop dermat tbc gilead may morphosi result societi clinic oncolog june eular june result juli roch result juli morphosi result tbc santherasarepta result may result may siemen healthineersqiagen result may holog result may result may elekta result june result juli philip result tbc ge result tbc roch result juli abbott laboratori result tbc danah result tbc labcorp result tbc quest diagnost result tbc sinclair pharmainterim trade updat tbc vectura azn result may result juli feedback fda meet track statu argenx result may result tbc readout month follow-up data tbc out-licens deal nda submiss result tbc
versu consensu upcom result
exhibit versu consensu compani report soon note consensu expect may small number contributor
factset capit market estim note indic limit number contribut consensu data
stockmetricconsensu fcst fcst fcst discoveri decemb yebtgmarch yeconvatecdecemb yeindiviorconsort medic newsflow item north america
north american colleagu believ key newsflow revolv around
on-going effort fda speed gener drug approv process
acquisit focus novel/rar indic doctor day
boston ny kol insight retin space duchenn muscular dystrophi
atop dermat car-t therapi
featur high level
fda activ clear
gener mix
opportun risk
eros remain high
underli driver
whilst direct read-across think worth highlight randal report
fda gener drug forum follow key takeaway fda
implement number chang gener drug user fee amend program
gdufa ii instanc includ establish pre-anda program
engag fda anda submiss introduct
disciplin review letter drl highlight possibl defici applic
anda sponsor earlier process underli theme fda
commit increas gener drug approv henc fda approv activ like
go remain high level said like go increas competit
price eros alreadi genericis market open opportun
brandon henri report hospit capital-expenditure read-through post philip result april
earn call manag suggest north american health care
custom continu focu prioriti around lower cost deliv better
outcom improv patient employe experi alongsid posit
momentum around value-bas care base prioriti new leadership hh
chines market philip manag expect market growth high-single-digit
y/i higher mid-to-high-single-digit previous expect
think stabl outlook hospit capital-expenditure north america alongsid posit
sentiment toward value-bas healthcar posit read-across siemen
healthin focus provid diagnost imag equip
healthcar provid enabl offer right therapi right time
specialist rare diseas
therapeut bolster bd
across hansa medic
unlik novarti brolo
favour abicipar
lucenti primari
patient benefit
steroid lost
studi design
market potenti
reimbursement/ logist
car-t therapi could
less hurdl two year
alexion pharmaceut acquir wilson therapeut swedish clinic
stage pharma compani one asset develop wilsonss diseas
note posit data on-going project launch
rare diseas high unmet need offer potenti
conveni safer possibl efficaci therapi believ acquisit
posit read across hansa medic platform target nich
organ transplant market high unmet need efficaci
conveni way transplant promis data think mani
characterist nich indic posit data novel platform recent
us healthcar team host doctor day kol boston ny see
follow read-across cover name
kol feedback valid market assumpt wet age relat macular
degener wet-amd cost treatment durat main driver
efficaci amongst treatment perceiv compar brolocizumab brolo
dose prefer one kol comment superior
secondari endpoint seen studi hawk harrier brolo compar
eylea result studi design favor brolo enabl endpoint
measur week post brolo week post eylea note abicipar
studi design sequoia cder favor abicipar lucenti
molecul endpoint measur week post dose
duchenn muscular dystrophi dmd kol comment steroid cheap
effici way treat patient delay loss ambul year
line heard santhera manag natur histori data
avail highlight steroid delay declin posit effect
steroid lost rate declin patient whether steroid
see posit santhera idebenon target patient steroid
failur replac steroid
kol mention increas reimburs hurdl atop dermat ad
treatment payor requir document failur immunosuppress treatment
approv expens drug dupix use moder sever
ad patient practic sever patient weekli dupix inject
need wait see studi design compar arm
think physician tri gaug efficaci potenti vs dupix
car-t therapi kol prior experi car-t clinic trial enabl
smooth transit practic comment substanti prepar
requir set infrastructur place clinic car-t therapi would
good stay power highlight launch us
late best case point think cart therapi
almost year lead time establish reimbursement/ logist could less
exhibit stock cover dougla miehm
titl link note
op technolog get fda approv
pli present addit ph ii data
alstrom syndrom
littl light japan us market
appear acceler
shpg sell oncolog busi
plu thought takeda
could suitor emerg
like overshadow
goodman make gud great initi
breakthrough takeda deal talk
opsen miniatur pressur sensor integr impella cardiac get fda nod today opsen announc
integr technolog within impella cardiac market client approv fda
approv trigger new mileston payment toward opsen remind two parti enter
agreement april connect op miniatur optic pressur sensor technolog applic circulatori assist
devic like impella cardiac result opsen grant exclus world-wide licens integr op
technolog circulatori assist devic
pli present data intern liver congress overnight promet present addit data ph ii
trial alstrom syndrom intern liver congress compani previous report posit heart liver data
week trial march time also indic would present find week confer
pli indic use techniqu call insulin clamp demonstr significantli reduc liver resist
insulin fat biopsi also show clinic improv drug-rel sae observ
revenu vs estim somewhat softer top-lin like attribut temporari sale
declin japan due supply-chain improv lower industri revenu gross margin stronger
estim importantli view nearli increas us ffr revenu
shire sell oncolog busi servier overnight shire announc enter agreement servier
sell oncolog busi busi includ market product oncaspar onivyd
shire reject takeda bid earlier report takeda made indic offer shire
shpg confirm offer fact made reject board bid repres takeda third
offer compani propos reject previous third bid repres premium
shire unaffect pre-takeda news share price repres premium yesterday close
offer consist cash equiti mix advis compani continu discuss futur deal
shire report result april open follow confer call et quarter expect
revenu vs consensu ep vs consensu overal expect result
overshadow on-going takeda/potenti acquisit situat
initi coverag knight therapeut outperform rate target knight manag transform
last compani paladin lab success stori conserv accret pharma acquisit manag
appli approach knight share trade near book valu see attract risk/reward profil
recommend share purchas investor seek long-term price appreci
report impli preliminari deal could announc tomorrow unconfirm reuter articl today suggest shire
takeda reach breakthrough deal talk preliminari agreement could announc wednesday
articl also note potenti agreement come takeda submit fifth confirm earlier today though term
disclos propos improv fourth cash compon bid friday accord articl
shire also expect agre extens wednesday uk regulatori deadlin would allow takeda carri
due dilig firm bid
takeda reach preliminari deal
preview cut focu
remain oper impact
result line expect
takeda increas bid late tuesday even shire announc term revis propos
receiv takeda fifth propos repres total bid approxim consist cash
equiti transact complet shire sharehold would takeda newli issu share
list japan us adr program shire board indic would will recommend propos
shire sharehold subject satisfactori resolut term possibl offer
crh report result april market close call may estimate compani first
quarter new bill unit result would expect much focu result impact
oper specif whether magnitud line manag guidanc
revenu vs forecast consensu shire report revenu
vs forecast consensu result gener line somewhat stronger
expect continu expect share price driven primarili on-going takeda situat
larg unev quarter
takeaway
come releas expect much quarter unless result significantli exceed miss expect
in-lin print morn like take backseat on-going takeda situat highlight thought
latter addit key takeaway
exhibit stock cover randal stanicki
titl link note
attent shift firmli mid-year data near-
sever import updat next month
matter focu
consid sale women busi per
new q-code medicar reimburs posit
surpris import read-through j-code
stock implic key near-term catalyst
rais target attract near-term trade path
question analyst day
thought post lunch near-term challeng remain
kmph releas provid opportun continu see event rich runway
importantli adhd late stage effort progress top-lin result pivot studi expect
mid-year us biggest valu opportun spoke manag post call enthusiasm
unchang share ytd see upsid still materi attract
leav might last major overhang follow competitor data step
event-heavi next month nerv block j-code agenda mid-apr symphoni data
follow like sever import updat share challeng
manag turnov help expect correspondingli low provid thought set-up
bloomberg report afternoon shortli close may consid sale women
busi would repres import first step toward unlock valu focu
thesi last unconfirm articl indic held talk advis ii
interest could come privat equiti valu billion iii decis made yet
award zilretta q-code today provid uniqu reimburs close half claim
import posit may overlook spoke manag afternoon bottom line
mean half zilretta base reimburs uniqu code ad eas
process physician importantli come clear posit read-through likelihood zilretta
award separ j-code share sold sinc shortli
earn help revers recent weak reiter op rate
advair repres one biggest gener profit opportun time billion us brand
revenu grab compani vy piec posit first earli
take detail look background profit opportun competit analysi report
advair sale expect billion gsk guidanc call cer
still sizabl one come longer durat given drug/devic formul complex
remain patent hurdl specif compani opportun dictat abil time get
fda approv process
revisit model outlook share stock sinc late jan almost declin
despit analyst meet major product catalyst near enthusiasm around gener sector
outlook remain tepid multitud sizabl pipelin catalyst gain focu next week set
attract near-term trade opportun rais target
lunch manag frank discuss around busi outlook near-term
challeng well understood debat support opportun build
begin get attent especi given remain appropri low near-term expect time
horizon matter deep valu stori becom increasingli interest
titl link note
anticip build cgrp entri read
snda nerv block offici approv big
posit surpris cc mon et
stand bull/bear debat question
co-host migrain panel annual boston doctor day discuss new cgrp therapi
evolv treatment landscap migrain import implic two cover compani
two oral cgrp candid develop ubrogep atogep million botox
migrain franchis revenu concern around impact cgrp entri ii teva whose
cgrp fremanezumab pdufa date think like delay due outstand wl api supplier
celltrion expect major competitor
close announc exparel snda nerv block approv coincid today
pdufa date follow volatil afternoon trade spark post broken label
supplement link fda approv drug websit subsequ remov assumpt
like jump gun move fda decid wait confirm publish
stock focu move higher recent week increas debat side see rang bound
catalyst-light stock near-term valuat rel spread level
bring sever import updat would help determin whether break rang
ebitda remain sector perform take closer look bull/bear debat
import question manag post
host call monday et code discuss late-friday nerv block
snda approv follow early-week dinner manag per note friday
upsid surpris stock begin push street number higher alreadi conserv
focus week analyst day
call/dinn lunch teva investor
pdufa extens announc elagolix thought
rel esmya
pivot busi last week includ manag lunch link day bo link late-
week nerv block approv link enter equal busi next five day begin
call discuss nerv block snda approv follow early-week dinner ceo/cfo
analyst meet wednesday three day meet investor discuss sector ny tx
also two-day gener drug forum april provid thoughts/color final also
publish report yesterday look bull/bear debat question manag
link focu seemingli pick
morn announc extens pdufa date nda elagolix endometriosis-
relat pain fda requir time review addit inform regard result liver function test
provid earlier year announc posit top-lin data two pivot phase studi
elagolix women uterin fibroid yet file expect compet esmya feb
fda extend review esmya uterin fibroid set aug target action date link
surpris given on-going review prac commiss european medicin agenc ema sever
report seriou liver injuri europ ema final decis expect may
titl link note
sever thing learn dinner manag
drill main debat
host dinner even manag includ ceo/cfo follow day separ
investor meetings/group lunch stock interest high share sinc apr pre-nerv block flat
still year-to-d room move higher near-term updat
catalyst still set summer
easl phase centaur data set present easl
today chang view
manag meet
see first gener vasostrict file
inevit still neg
submiss reiter host manag meet
week
cgrp primer market model address
import question ahead cgrp entri teva
weak surpris earli cross-read view
analyst meet attempt showcas strength pipelin diversif better
rememb temper expect drove late day weak step back near-term
 asid still see potenti upsid summer pipelin catalyst outlook also remind us gener
compani uncertainti remain pipelin convers need
morn present year data phase centaur studi cenicriviroc cvc adult nash
patient easl follow confer call discuss result top-lin data present last septemb
alreadi seen top-lin releas patient cvc two year treatment see
signific differ rel pbo composit endpoint improv fibrosi least stage
worsen nash trial design power year analysi year analysi exploratori
overal continu exclud model
fda host two-day fda gener drug forum apr fda subject matter expert
offic gener drug ogd offic pharmaceut qualiti opq present varieti topic relat
gener drug applic review process groundbreak develop forum
highlight fda unrel focu increas access gener drug
survey orthoped surgeon look earli patient feedback around zilretta use physician view
recent reimburs chang realiti still earli survey show see
favor earli feedback patient experi encourag host manag road
two day next week look launch color
op announc morn submit fda accept anda vasopressin inject
gener vasostrict vasostrict sp singl largest product sale million
revenu gross profit estim year time gener vasostrict file known though
clearli view inevit someth discuss manag apr lunch nevertheless
repres move closer competit risk around compani largest product anticip drive
weak share today
morn announc complet human factor hf studi valid revis direct
use dsuvia complet studi compani expect re-submit nda on-track
prior timelin detail note straightforward path dsuvia resubmiss expect catalyst-
cgrp migrain set enter earli may drive billion us market time import
implic teva report design primer investor look better
understand migrain market ahead sever import near-term event includ american academi
neurolog meet apr upcom fda cgrp action date
earli morn nv report includ sandoz perform metric continu serv earli
baromet gener sector perform given size scale busi overal take weak
us result serv earli data point environ remain challeng ou perform
continu solidli stabl head quarter expect low given continu challeng seen
link link still surpris magnitud weak us busi
titl link note
revenu last year pull global sandoz revenu constant
currenc cc eros larg us would wors ou result solid
cc sandoz guidanc unchang still expect broadli line slight declin
gener pharma addit sandoz/gener color
nv call broad specialti pharma takeaway
got nv earn call look specif updat around sandoz
busi read-through gener coverag well broader commentari note
erenumab/cgrp partner cross-read teva/agn
earli talk shpg skeptic high deal unlik
shpg head fake non-ev reaction strong still
inject debat aesthet toxin/cellulit focu
cgrp data point cgrp debat read agn
fre termin deal vigor defend stock
link litig
file litig enforc outcom expect step
offici
share intra-day press report confirm earli talk potenti acquir shpg
share ltm pressur high strateg revisit platform point asset
sale sinc sept avenu pursu shpg deal surpris like get materi push-back
view
today clear investors/w want see shpg deal confirm pursu uk
take-over law like ad confus remind understand pursu broad strateg
review reaction support view push sinc oct think asset sale larg deal
make sens
host aesthet panel annual ny doctor day discuss rang treatment toxin
filler kybella xiaflex procedur coolsculpt mean compani vy share
aesthet market physician view botox posit remain solid unlik see
much share loss discount toxin cover long durat option cover
potenti take meaning share biggest surpris magnitud enthusiasm around
cch/xiaflex cellulit drove investor focus/quest discuss follow panel physician see
overal aesthet growth continu robust rang consist check
host migrain panel annual new york doctor day focu evolv
treatment paradigm migrain heard mix messag confid resili
botox migrain franchis temper safeti concern oral therapi teva continu see risk
delay fremanezumab compound potenti loss first mover advantag encourag
read-through long-act toxin though remain far commerci
fre announc termin agreement acquir cite failur fulfil sever close condit
base least partli alleg materi breach fda data integr come
investig ahead apr would trigger extens follow announc
intent vigor enforc mean stock like link litig outcom
follow statement yesterday plan vigor enforc right pursu deal close
respons fre move termin deal compani file delawar chanceri court
reiter on-going investig data integr issu found fact would result
materi advers effect busi
titl link note
updat set-up upward revis
market close symphoni report march institut sale data million exparel in-
line/slightli ahead consensu believ million impli year-over-year growth
one less sell day sequenti growth februari link
learn manag trip
buyer inflect
acquisit somerset small deal
encourag data point
 dzuveo receiv posit chmp opinion
review complaint add color fre claim still
see path close
achiev ii data add case ubrogep
top sector takeaways/cross-read lunch
host manag day meet focu launch zilretta level confid
around execut meet coincident term time given focu launch leav
feel comfort specif factor drive view bottom line continu see meaning
inflect come yet reflect stock reiter op
morn announc reach definit agreement acquir
india-bas subsidiari wintac million cash somerset us-bas gener drug manufactur
special steril inject ophthalm drug us market portfolio includ commerci
product pipelin product submit fda transact
bolster portfolio inject product provid anoth low cost manufacturing/r site
india via wintac deal expect close end overal deal view
materi reflect year cash flow remind manag continu push
forward effort build platform like addit
morn announc committe medicin product human use chmp ema
recommend approv dzuveo europ dsuvia us chmp posit opinion refer
european commiss respons grant central market author eu
expect european commiss make decis within approxim month
review legal complaint perspect shed lot light alleg
data integr issu ftc process expect materi data integr issu debat
color like come fre overal yet convinc issu rais far level
deal break
top line data releas today show compel efficaci arm safeti concern remain littl
debat ubrogep work debat around commerci opportun competit
dynam expect low ubrogep contribut beyond chang
model/peak await import long-term safeti data
host lunch new hikma ceo siggi olafsson well-known/tenur gener execut prior
join hikma announc feb link president/ceo teva global gener medicin group addit
sever senior leadership role year lunch focu hikma strateg posit link gener
industri outlook product hikma pursu gener cross-read includ xyrem
exhibit stock cover glenn novarro brandon henri
titl link note
week ahead spring break quiet week
preview pharma pois anoth
expert call event
note take-away event stock perform si updat
analysi indic exceed consensu revenu estim march quarter power anoth strong
perform segment suffici catalyst sentiment revers among investor
launch recoveri share price perform balanc recommend buy result due april
trump threaten tariff certain medic devic hospit capit equip categori good import
china worst case scenario estim trump tariff would result hit med-tech industri
robot expert call lead annual sage confer seattl robot breakfast annual sage confer
seattl hold investor event sage med-tech sector perform ytd large-cap med-tech univers
lag bp sector thought favorit idea remain bullish med-tech
recommend major stock univers recent sell-off market sector creat favor
risk/reward
medic suppli devic large-cap
investor posit earn display bia toward large-cap med-tech compani health
equip suppli index gener total return outperform percentag point currenc
strong tailwind revenu growth averag valu dollar index lower y/i
large-cap med-tech compani coverag estim fx add averag year-over-year revenu growth
posit
radiat oncologist survey mix
believ radiat oncologist survey larg posit point continu strong mid-single-digit y/i market
growth abil product portfolio continu drive share gain compani howev
disappoint includ less optimist halcyon hyperarc feedback continu cautiou commentari proton
larg posit cover mix elekta cover radiat oncologist
expect strong mid-single-digit y/i growth practice/hospit radiat oncolog budget continu strength
seen survey radiat oncologist us-bas eu-bas radiat oncologist expect
practice/hospit radiat oncolog budget mid-singl digit y/i expect y/i world-wide
radiat oncolog market sale order growth expect largest system market share gainer
next sever year expect largest softwar share gainer radiat oncologist suggest
manufactur like gain linac system softwar market share
survey result give us increas confid execut replac cycl opportun low expect
stock may enough send share higher howev result also show still work convinc
radiat oncologist outsid exist instal base system differenti enough
purchas practice/hospit
titl link note
result offer insight cardio ortho
robot volum grow two major academ center spoke host call two high
volum robot surgeon one focus gener surgeri colorect gener surgeon estim robot
volum hospit y/i biggest growth hernia repair liver colorect procedur hospit
also seen uptick robot pediatr ent procedur separ colorect surgeon seen y/i increas
robot procedur hospit seen broaden robot procedur area benign gyn ent thorac
tuesday april report earn dial-in estim ww revenu fce
ep fce report tuesday april market close dial-in
estim ww revenu fce ep fce report wednesday april
dial-in project ww revenu ep fce fce
respect med-tech team host doctor day april new york schedul
includ min hour session doctor surgeon variou subspecialti includ foot ankl shoulder
radiat oncolog hip knee electrophysiolog diabet surgic robot spine tavr
attend societi american gastrointestin endoscop surgeon sage annual meet
result revenu ep
revenu exceed forecast consensu ww revenu forecast
consensu oper sale growth organ growth in-lin figur currenc favor impact
quarter sale three segment estim segment primari sourc
upsid geograph oper growth revenu revenu
med-tech readthrough continu
lose share orthoped spine
md revenu came consensu underli busi appear stabl sequenti recon growth
fell short expect even account sell day impact continu lose world-wide spine market
share trauma perform improv electrophysiolog busi show strong growth nj surgeri
busi exceed consensu
host surgeon breakfast sage dr dietmar stephan gener surgeon siegen germani
pharma overcom devic weak
revenu ep consensu
march quarter result along line expect strength segment partial off-set
continu uneven growth trend seen medic devic past quarter expect pharma sustain
strength balanc perform devic consum need improv share recaptur
premium
sale exceed forecast broad-bas strength buyer pullback
provid detail robot program upcom may consum medic devic review
announc ethicon subsidiari execut definit agreement enter strateg collabor googl work
lifesci team advanc surgic robot verb surgic announc demonstr first digit
surgeri prototyp collabor partner ethicon endo-surgeri verili life scienc formerli googl life scienc
cnbc recent suggest verb surgic invest robot joint ventur success
option buy alphabet share jv employe current work verb surgic accord cnbc
around develop googl brought assist effort
titl link note
strong start put top-half ep
guidanc line sight
busi week med-tech earn
ew report
surpris quarter reiter
result guidance/consensu
result consensu full-year
solid demonstr earli success
rais estim reflect upsid
revenue/ep guidanc rais
gross order came
new product momentum geograph divers deliv anoth quarter high singl digit organ revenu growth
double-digit ep growth high end revenu guidanc remain realist target yesterday volatil trade
share accur depict strength underli fundament instead present attract buy
ew kick earn week upsid possibl guidanc could move higher expect high codman
deliv radiat oncologist survey larg posit guidanc look conserv
leadership chang unlock valu long-term patienc need one strongest organ top-line grower
univers
electrophysiolog posit bsx watchman diabet posit libr spine posit
neg extrem posit neg hip/kne posit mix neg
radiat oncolog posit mix elekta robot general/bariatr surgeon posit
philip report organ sale order growth consensu philip report result morn
revenu consensu y/i organ sale growth consensu vs y/i
growth revenu growth driven y/i growth matur geographi y/i increas growth
geographi middl east turkey india latin america north american sale y/i western european sale
flat y/i matur geographi sale increas y/i earli manufactur result point continu strong world-wide
hospit capit spend market market report world-wide hospit capital-expenditure sale y/i
constant currenc vs earli world-wide hospit capit spend result look strong
collect evid tavr survey two recent doctor day chicago nyc dinner event lead tavr
expert point scenario limit upsid ran contrari prevail investor sentiment reflect ytd
return vs base activ after-market risk/reward assess favor buy weak
results/guid appear good enough support premium valuat
report strong result rais revenu guidanc howev chang organ revenu growth full-
three product categori better rel estim intervent cardiolog ic neuromodul
share common thread name new product drive growth overcom weak select categori pacer
stent quarter perform increas confid organ growth exceed beat-and-rais cycl
continu
updat model reflect solid perform css favor fx maintain price target
sector perform rate
recent survey result give us confid radiat oncolog market growth remain solid gain near-term
share despit share cheap question remain time sirtex revenu reacceler
manag abil exceed cost capit target reason time-frame sirtex
titl link note
organ revenu growth ep
medic suppli
result slightli better expect continu believ leadership chang unlock long-term
report strong top-line result rais revenu adjust cash ep guidanc
consensu ep estim rebas believ compani posit start meet beat
consensu expect believ new leadership unlock valu share remedi issu north
west campus fill key product gap intern innov acceler top-line bottom-lin growth
remain offens product portfolio pipelin balanc sheet power sustain top-tier revenu growth
addit oper leverag begin shine manag commit minimum
oper margin expans buyer pullback
believ capit deploy potenti driver stock upsid near medium term addit
compani analyst meet may could provid potenti catalyst stock expect manag provid
deeper dive pipelin well long-term financi target
busi week med-tech earn ktwo elgx kick earn next week april
market close ktwo report may close report may market close elgx
report may market close report may market close report may
market close report may market open report may market close
annual survey electrophysiologist cover volum price share trend devic volum share trend
af ablat growth trend novel devic watchman emblem s-icd micra tp
smid-cap med-tech start report week report highlight select smid-cap stock coverag univers
exhibit stock cover frank morgan
titl link note
vertic integr consumer
heel propos vertic integr deal cvs/aet ci/esrx reportedli eye
bigger move healthcar new consum market type transact
news nashvil
weekli perspect healthcar industri
holiday shorten week end march healthcar servic stock outperform broader market
 health servic select index spsihp downtick versu declin
 ambulatori surgeri strongest perform sub-sector last week
acut hospit remain flat vs gain prior week manag gain vs
declin prior week senior live weakest perform sub-sector last week
updat estim reflect complet merger almost famili
expect
news nashvil
weekli perspect healthcar industri
manag final rule obamacar
exchang design increas flexibl
access return author state
manag health
analyz geograph overlap strateg
final notic medicar advantag plan provid net increas capit rate
exclud expect increas risk score final expand coverag non-skil home health
along propos perspect last year final rate bp better propos
previou year bp lower propos believ payment updat view
posit manag stock expand coverag in-hom servic posit
stock downsid move ahead propos chang egwp reimburs
formula use higher proport encount data result slight offset rate
week end april healthcar servic stock outperform broader market health
servic select index spsihp gain versu declin
health strongest perform sub-sector last week includ
close afam merger acut hospit gain vs flat perform prior week
manag gain vs gain prior week skill nurs weakest perform sub-
sector last week
chang final rule design build previou action taken trump administr
continu theme return author insur market state interestingli rule
acknowledg despit individu mandat elimin tax reform bill
essenti repeal previous proclaim presid trump recal
publicly-trad mco effect alreadi exit exchang marketplac final rule
design enhanc flexibl reduc burden would expect meaning increas particip
near term
theme consolid mean healthcar industri remain forefront wall
street thought sector regul foil earli attempt among payor consolid
momentum consolid shift follow recent possibl vertic integr
payor servic provid perhap even retail
titl link note
market concern possibl threat strateg
continu pressur industri fundament
news nashvil
weekli perspect healthcar industri
beat rais solid growth
add april show
strongest growth recent
continu out-performance strong visibl
share report termin contract evhc disclos court file last friday
file arbitr respons lawsuit file evhc march compani alleg
fail add affili new evhc provid group unilater reduc reimburs rate
go term agreement
overal perform senior hous industri remain weak declin occup across
product type continu deceler rate growth perform like hurt strong flu
season given weak start year along impact recent futur new competit
open like remain pressur near term
week end april healthcar servic stock under-perform broader market health
servic select index spsihp gain versu gain
skill nurs strongest perform sub-sector last week larg reflect movement
rel low price acut hospit uptick vs gain prior week
manag gain vs gain prior week ambulatori surgeri weakest perform
sub-sector last week
adjust ep vs consensu beat result reflect
continu strong growth across diversifi busi line saw double-digit increas
earn offset impact flu lead manag increas guidanc
releas medicar advantag part enrol data april ad net
member roll sinc march bring total enrol membership country-wid
increas sinc april last year reflect increas penetr medicar advantag membership
among medicar elig popul year-to-d membership grown reflect larg
bolu new member join roll recent open enrol period medicar part
enrol downtick sequenti increas sinc april last year
anoth impress perform quarterli perform busi line post
double-digit earn growth underli busi trend remain strong enhanc
acceler invest known headwind later year factor guidanc
believ visibl remain good rais pt slightli
expert call healthcar labor trend suggest
call healthcar labor expert indic low likelihood widespread shortag nurs
nation level view posit overal healthcar servic provid howev pocket
concern requir attent innov privat sector
beat strong margin
post strong start year result significantli exceed consensu estim
ahead manag expect reflect solid top-line growth impress margin expans
guidanc maintain buyback like continu upsid bia earn
titl link note
announc miss divestitur sound
provid comp evhc
news nashvil
weekli perspect healthcar industri
vertic integr continu hospic
ipp ltch propos acut rate
ltac get rule would
 beat rais
street closer manag
beat rais visibl remain solid
sale price fm sound unit come surpris time given manag enthusiasm
coordin suggest valu evhc physician servic segment servic line
sound deal pend unh/dmg deal exactli compar provid insight
valuat evhc base current comp believ valu evhc busi
aggreg ev conserv assum busi held minor
partner combin net debt give credit amr proce would suggest valu
evhc north
week end april healthcar servic stock outperform broader market health
servic select index spsihp gain versu gain
temporari staf strongest perform sub-sector last week acut hospit
downtick vs uptick prior week manag gain vs gain prior
week reflect solid beat rais tuesday skill nurs weakest perform
sub-sector last week
acquisit interest servic strengthen care
deliveri platform addit approxim hospic program serv state estim
approxim ebitda multipl transact demonstr strateg import vertically-
integr care particularli serv need medicar advantag member
releas propos rule acut care ltac hospit tuesday even includ
respect market basket updat higher dsh payment acut pp expect partli
off-set adjust requir ltch-pp payment would see slight increas would
elimin rule addit propos reduc number requir report measur
across qualiti value-bas purchas program help reduc administr burden
hospit recal final rule typic slightli better propos perspect
provid publish earli august take effect octob
adjust ep approxim estim consensu
larg driven margin improv mbr came better expect lead manag increas
came consensu larg reflect softer-than-expect result behavior due
primarili restructur start-up cost well weather-impact outpati volum lead margin
contract meanwhil acut busi perform line expect top-line ebitda
growth margin expans guidanc remain unchang though street quarterli cadenc need
solid start year beat rais better-than-expect medic cost perform increas
estim price target
titl link note
strong start year anoth solid beat
street miss wors management view guidanc
post anoth solid quarter strong top-lin growth segment includ continu strong
organ volum growth health hospic segment well solid ss discharg growth
price irf segment adjust ebitda came well ahead expect solid top-lin
perform lower bad debt oper leverag driven improv labor manag product
gain manag rais top-lin ebitda ep guidanc reflect solid start year
miss vs intern expect larg street miss factor restructur
start-up cost behavior health fell slightli short budget acut perform consist
expect
exhibit stock cover brian abraham
titl link note
limit read-through rtf continu
chang near top hous celg look get
back track
earn preview select biotech
takeaway boston doctor day cf car-t
epacadostat fail expect downsid still
share trade morn alkss rtf file depress drug believ investor
draw parallel likelihood lumateperon first-pass approv schizophrenia acknowledg
similar itci lumateperon seek approv unmet need
large-market neuropsych indic base mix data believ mani key differ
limit signific read-through one regulatori situat opportun speak
manag continu see reason probabl first-pass approv itci luma base exist
data today downsid improv attract share reward/risk basi
afternoon celg announc departur presid scott smith one highest rank
execut compani report directli ceo mark all
spent time road management team follow discuss see interest net favor
near-term setup share like continu good exondi commerci uptak signific revenu
expans opportun posit microdystrophin signal would impli initi chmp pushback exondi
look like probabl alreadi bake share reiter outperform strong diversifi dmd
earn around corner provid thought select larg mid-cap biotech compani
within coverag overal earn gener okay cover mid/large-cap co allow
season weak believ clinic trial success increas activ import
help improv sentiment given renew drug price competit life cycl concern across sector
preview celg detail estimate/pric target chang
rbc healthcar team host doc day boston includ kol cystic fibrosi car-t/cellular therapi
depress hiv ibd migrain multipl sclerosi sma/dmd overal believ takeaway
posit increment favor mix posit
neg celg aldr glpg
announc trial evalu use epacadostat pembro metastat melanoma
meet primari endpoint expect meet secondari os endpoint stock
well high believ expect come significantli data sens
expect stock could trade high follow neg epacadostat result continu
see floor valuat account jakafi probability-weight baricitinib royalti est
net cash around low dcf basi zero epacadostat model note
account potenti posit extens jakafi life cycl beyond pipelin success
titl link note
high enthusiasm depress drug emerg
ph iii epacadostat data suggest drug inact new valuat assum contribut drug
meaning cost save out-year program inevit wound without epa lower-
upsid also lower-risk stori solid jakafi fundament potenti favor bari adcomm
pipelin prospect could see share bounc back toward fairer valu lower tgt
share pull back high part due broader sector weak well
perceiv lack catalyst howev especi follow deep dive discuss yesterday director
major psychiatr treatment research center believ fundament competit posit
upsid opportun brexanolon strong ever see recent share weak provid
novarti avx deal breath life sector quick
read-through coverag context
novartiss deal avx morn sizeabl premium could kick start sector
await view see posit read sector overal anticip
major deal trepid drug price risk-highlight neg catalyst keep sentiment late
novarti plan acquir avx increas pt
align deal price
earli morn novarti announc propos acquisit avx premium
friday close price valu compani see high likelihood deal close
agreed-upon term rais pt maintain sector perform
updat easl day
stand among crowd ad hbv
asset pipelin
ipf updat detail studi set path high
attend easl congress pari access poster avail earli view well
addit poster oral session present today -- notabl data pbc nash potenti
addit bezafibr easl guidelin second-lin option pbc nash combo stellar enrol
cvc nash data spent time speak compani manag investig repres
kol note audienc reactions/quest
attend easl confer opportun attend present enta novel
hbv core inhibitor candid view poster new preclin data sit ceo discuss
new develop overal came away impress hbv asset potenti best-in-class core
inhibitor highli differenti preclin profil vs core inhibitor data to-dat addit view
potenti differenti lipid promis though wait clinic elucid
on-going ph ii data hbv core inhibitor remain earli includ model believ
addit progress candid select clinic progress along rsv data year could
gener stock upsid though remain sp believ share fairli account hcv royalti nash
even glpg disclos detail registr ph iii ipf along
potenti promis pipelin candid typifi sound discovery/develop engin though program
remain earli continu hold risk despit increment clariti trial design time believ
glpg share fairli valu data suit program matur maintain sector perform
titl link note
read-through settlement potenti
last night celg ad suit on-going revlimid anda litig drl addit five rem patent
believ addit lawsuit simpli formal read-through potenti nt settlement
celg gener extend recent cancel markman hear
updat easl day
posit updat easl nash combo
promis data emerg aacr
updat easl day takeaway
attend easl congress pari view addit poster oral session present today
-- notabl mdgl nash data icpt pbc edish analysi pois pbc substudi pfe ph
data also spent time speak compani manag investig repres kol
note audienc reactions/quest
attend easl present ph ii combo nash studi follow present came away
feel confid combo approach view combo promis
synergi could replic on-going larger ph ii studi announc ph iii
stellar studi complet enrol tee ph iii readout pivot selonsertib nash program
next year reiter outperform see solid hiv foundat potenti increas valu nash
afternoon market close abstract ph ii studi agonist pembro head/neck
cancer releas ahead present monday initi efficaci data small number
patient believ epacadostat experi remind caution need interpret open-label
checkpoint combo respons rate look encourag achiev pr achiev
sd higher respons rate typic seen similar popul head neck cancer
treat pembro alon higher bar believ would repres meaning respons rate
importantli notabl safeti issu limit flu-lik symptom headach injection-sit
reaction fatigu
high-profil abstract meet new respons rate data agonist
head/neck cancer discuss see note believ show promis orr indic
potenti activ difficult-to-treat set howev note addit abstract also releas friday
afternoon updat melanoma data previous unveil last year recal promis
nave patient obtain cr/pr combin pembro pd-experienc patient
lower respons rate
attend easl congress pari provid overal takeaway follow late-break session
includ data roch hbv core inhibitor nv fxr agonist pbc nash psc
believ question come gild ph ii nash studi present easl
consist data degre de-risk selonsertib combo go forward
attend present easl today opportun speak gild liver diseas
area head remain optimist prospect portfolio believ data inconsist like
due small size studi vari baselin characterist healthier pt
limit
imaging/biomark endpoint follow-up continu see promis direct signal
multipl shot goal nash program believ substanti bake share
titl link note
orr h/n cancer
rxcheck biktarvi earli veloc launch
document show nv bid isol interest
poster updat data pembro head/neck cancer releas oppti
discuss new result extens compani add pt respons rate slightli lower vs
abstract still look would expect pembro alon though especi follow
epacadostat experi cautiou overinterpret small immatur open-label io combo dataset
continu see promis signal potenti activ good valu share given solid heplisav
analysi launch prescript trend suggest biktarvi may come consensu sale est
howev strength across franchis enabl overal top/bottom-lin beat biktarvi rx run-
rate coupl posit real-world feedback sign overal hiv share gain suggest post
stronger-than-expect biktarvi sale full-year reiter outperform increas growth visibl
afternoon attend analyst day nyc came remain confid compani add
growth opportun market dmd drug upsid potenti show clear promis sma
earlier-stag pipelin reflect interest scienc though still need time matur share
appreci sinc start year believ opportun balanc commerci
development risk better captur
releas contain chronolog avxs/nv negoti preced novarti acquisit
compani reveal multipl interest parti except nv ultim back away due price
combin stage compani suggest degre moder believ confirm
nv interest isol sever compani remain readi will make move pre-
commerci biotech market cap rang meaning premium expect maintain
enthusiasm around momentum smid-cap biotech could help catalyz generalist return
space perhap large-cap name well particularli trump drug price commentari
alway thought could natur potenti acquir avx given initi entrench
sma space spinraza launch potenti acquisit help defend franchis vs gene
therapi test combin cash posit potenti commercial/regulatory/manufactur
synergi could made avx valuabl other base last night file
avx believ involv potenti acquisit process least end
describ detail note earlier today found first interest parti
appear prior engag avx believ roch second interest compani
lengthi fda brief doc incy/lli baricitinib post interestingli reveal highli
dichotom view among fda staff benefit/risk profil baricitinib key dose
highlight mani already-known concerns/quest whether efficaci benefit suffici
overcom like increas safeti liabil whether mg approv given limit data
whether drug approv given avail jak inhibitor ra
titl link note
nt pot reduc drug price overhang large-
show promis increas smn protein
level await detail poster present
takeaway new york doctor day migrain ms
ibd car-t dmd/sma cf nash mm depress
fda brief document post morn upcom baricitinib adcomm show signific
debat within agenc benefit/risk drug see note recal gild/glpg filgotinib
gener jak inhibitor class also test ra well diseas despit scrutini
see major read-through either way filgotinib -- one hand review made point thrombosi
like class effect suggest consid drug profil individu though hand
document highlight high safeti bar ra approv bari lower dose would reduc ra
competit could improv filgotinib commerci posit though filg could get treatment
agenc also note benefit/risk filg would like less scrutin ibd account
out-year prob-adjust sale estim anyway remain rel posit filgotinib potenti though
believ optim agent alreadi reflect glpg share vs share
largely-unnot legal rule state drug price transpar combin anticip
rel benign trump drug price speech could help set stage improv sector sentiment
combin increas action tend highest late-summ seasonally-soft
earn facilit return generalist fund flow biotech space appreci large-cap
currently-depress valuat back half
believ collaboration/invest build upon pre-exist relationship initi success
market spinraza program account compani scientif
development align provid first choic target within varieti neurolog diseas
area also pay mileston tier royalti pay clinic
develop regulatori process commerci post opt-in though total cash outlay
discoveri deal may rais eyebrow fact cash equiti invest note
one commerci product would make deal valu posit make palat
friday afternoon emerg scienc abstract oral splice modul type sma
releas four week treatment increas smn protein level baselin
observ patient though look addit detail full poster present
tuesday fulli contextu result includ mean/median protein express chang
dose patient number patient includ analysi updat surviv data full cohort
believ data promis consist propos mechan await clearer clinic
correl clinic data remain earli mostli low dose
rbc healthcar team host doc day new york includ kol migrain multipl sclerosi ibd
car-t/cellular therapi dmd/sma cystic fibrosi nash multipl myeloma depress overal believ
takeaway posit aldr iv epti oppti jak ibd prospect nt yescarta uptak
reauth issu amen golo/casi symdeko switch potenti enrol iv
recept mdd translat net mix celg safeti durabl ozanimod
role bcma caution glpg filgotinib cf translarna emflaza flint
titl link note
morn announc acip recommend hbv vaccin heplisav-b publish
mmwr provid written endors acip support posit recommend
note mmwr public particularli posit conveni element note benefit protect
dose administ month make import option prevent hbv perhap even
notabl pr state market respons heplisav-b exceed expect
believ share weak friday part due insid sell well larg discoveri deal
perceiv potenti neuro co acquir howev view non-fundament friday
detail in-lin brexanolon data today on-track nda file continu bullish physician feedback maintain
confid believ remain substanti underappreci opportun
watch live today fda panel baricitinib rheumatoid arthriti recal receiv
materi royalti earli morn session compris detail overal data ph iii
program kol perspect
europ unclear recept pulmonari
note specif schedul oral explan discuss exondi tomorrow
local time et continu believ initi pushback like potenti announc
neg trend vote given preced compani note strict rapporteur dystrophin
watch live today fda panel baricitinib rheumatoid arthriti recal receiv
materi royalti fda present panelist reaction conclud overal believ
tone agenc meet overal seem consider less neg brief document
base-cas outcom rais
watch live today fda arthriti adcom lly/inci baricitinib recal jak inhibitor
class gild/glpg filgotinib rheumatoid arthriti filgotinib import potenti lt revenu growth
driver believ anticip futur econom drug compris larg portion glpg
current valuat futur success import compani though inflammatori bowel diseas
like larger ultim market opportun filgotinib ra also compris meaning out-year
today fda adcomm vote favor dose baricitinib unfavor dose given vte signal
view base case reduc bari initi market opportun ra preserv royalti
potenti futur indic approv net-net target increas slightli base
increas po offset lower sale estim still view under-valued
soft ms driven inventori fluctuat reflect matur franchis expect lt spinraza number come
help clarifi underappreci mainten dynam could see increment downsid optic
light top-lin noth initi chang core thesi exist franchis gener stabl
impact bd increasingli import gener enthusiasm long-term growth potenti inflect
titl link note
soft stem spinraza season
aldr present month data dose eptinezumab first ph iii episod migrain
promis trial overal data valid eptinezumab persist effect addit dose
support solid profil allevi concern efficaci cgrp mab might wane time
believ market dynam driven larg commerci factor marketing/pay continu see
uniqu opportun iv support recent neurologist convers -- peak sale estimate
see underappreci valu aldr share
ms franchis look reason stabl forese futur despit inventori fluctuat lighten though
spinraza dynam illustr challeng growth pictur like reset out-year expect de-risk lt
revenu growth driver becom tougher find within portfolio though current level low expect
could enabl upsid success expand pipelin bd initi buyback could help floor
adjust price target
firefish studi oral type sma present yesterday releas public last
night believ newest data cut promis addit patient trial
addit death sinc two report last januari infant lost abil swallow requir
perman ventil given observ includ three patient month old
believ may indic activ type sma though difficult assess sure point
whether true treatment effect sinc patient sub-therapeut dose dose
start averag month age limit inform mileston function data
certainli direct justifi move forward maintain promis drug potenti believ
share reflect opportun risk market pipelin program could see add upsid
show clear activ data cut throughout year
last night celg circul present ozanimod ms ph iii safeti highlight
observ major activ metabolit drug recal celg receiv rtf fda
key pipelin drug februari base compani color clinic trial list sever other
specul might relat metabol inconsist observ late develop
dive cover compani grant patent publish applic gain uniqu insight
priorit undisclos program life cycl strategi
solid sale strong data bolster view
top-notch lt growth stori
solid quarter cf sale show strong continu commerci momentum addit posit data
second next-gen corrector movement ph iii believ provid anoth shot goal de-risk
futur expans entrench add work requir non-materi revenu growth oppti
continu believ fundament strong high-qual growth stori biotech warrant add
solid quarter cf sale includ strong symdeko launch addit promis data
continu look consist anoth cf ph iii program teed combin improv lt cf
growth prospect leadership remain attract valu clean high-growth fundament strong stori
adjust price target
titl link note
advanc bispecif clinic expand
data approach provid clariti portfolio
takeaway strong heplisav-b
recept cautiou optim
ubrogep liver ae optic favor cgrp mab
year-end review mru highlight clinic progress partnership simcer ono
provid outlin cadenc data readout expect continu like novel bispecif
platform long-term prospect portfolio program like though share could trade line
matur de-risk datapoint adj tgt model updat
updat increment though path set new datapoint ahead filgotinib maintain high
enthusiasm asset continu reason posit expect filgotinib remain cautiou
cf balanc portfolio interest earlier pt model updat
spent last sever day road management compani show high enthusiasm
heplisav-b lt prospect appropri cautiou optim earli data time re-affirmed
view heplisav provid strong sustain valuat floor signific io option minim
reflect share reiter outperform rate
chmp meet highlight came morn make mention exondi recal oral
explan taken place earlier week april base commun compani
believ final decis come chmp meet may may
report result second ph iii ubrogep -- rate liver enzym elev
high focu class oral cgrp antagonist -- report alt/ast elev uln overal
continu believ earlier-stag oral cgrp agent may liver risk especi use daili prophylact
even approv long-term still carri liver risk baggag could limit use among conserv
neurologist vs mab like aldr epti continu view aldr well-posit competit within
mab space across cgrp class overal see nt upsid oppti bla timelin clariti
exhibit stock cover kennen mackay
titl link note
ceo add rare dx global commerci expertis
transform year come
morn announc appoint dr carsten thiel ceo replac dr timothi miller
transit chief scientif offic somewhat unexpect shift posit well months/year
ahead compani transit late stage registr develop sever lead product near term
commerci becom key prioriti compani growth
nerlynx nccn rec indic high unmet need
mbc ahead nala read-out
downgrad sector perform concern path
forward peanut
cyramza success littl
opportun
takeaway post-sgo ovarian cancer kol
morn announc nccn guidelin cancer recommend nerlynx treatment
option metastat breast cancer mbc patient brain metastas specif guidelin
recommend treatment nerlynx capecitabin recommend uniform consensu appropri
nerlynx paclitaxel recommend consensu appropri base respect
nefertt studi
downgrad sector perform maintain specul risk qualifi reduc price target
increas skeptic regard path forward peanut allergi see post-peanut data credibl
concern creat unfavor risk/reward asthma readout success remain
somewhat price anticip show benefit vs placebo asthma caution could
challeng interpret vs biolog competit
morn announc cyramza studi met studi primari endpoint overal
surviv os secondari endpoint progress free surviv patient detail
surround level benefit disclos press releas cyramza histor data lead us
view drug signific threat view peak penetr market
cabo reason light increment competit cyramza potenti futur checkpoint
immuno-oncolog combin current assess studi
last week host investor call lead academ gynecolog oncologist special treatment
ovarian cancer oc patient discuss key takeaway recent societi gynecolog oncolog
sgo annual meet well current evolv oc treatment paradigm
mackay biotech takeaway boston doctor
takeaway physician/kol panel focus opthomolog inherit retin diseas
ovarian cancer tsro migrain peanut allergi
dermatology/atop dermat
mainten fda approv expect label
open argument cleanest parpi
expect today fda announc approv rubraca recurr ovarian cancer mainten set
indic statement line competitor zejula tsro lynparza azn importantli
addit updat made rubraca warn precaut section see valid
rubraca known liver enzym elev transient lab abnorm clinic concern
titl link note
buy dip modul temporari halt read-
wilson acquisit cast away bd kick
bang
remain wilson market dynam
posit best-in-class tki
today late-day share weak attribut clinicaltri gov updat roch
mainten modul studi link indic recruit suspend trial
specif april modul trial updat updat submit april cite follow idmc review cohort
data temporari recruit halt whole studi temporari halt randomis cohort
undertaken modul cohort assess cotezo combin exel/roch cotel cobimetinib
tecentriq atezolizumab combo trial studi top-lin
compil result quarterli investor sentiment survey question focus overal sentiment
toward biotech sector remaind year well investor view key catalyst debat
pertin coverag univers investor particip long-onli long-short specialist
generalist celg cover brian abraham cover kennen mackay
morn announc acquisit wilson therapeut ad much-need late-stag
clinic develop asset lead drug novel oral copper-bind agent develop wilson
diseas previous spars pipelin investor increasingli focus bd effort diversifi
revenue/valu away anticip transact could help add posit
sentiment stock
look toward financi result rx script analysi suggest potenti dupix post strong
us beat cabometyx see slight beat rcc launch script trackabl anticip
soliri beat though concern nerlynx tsro zejula print revenu estim
analysi coverag commerci stage product detail within
morn attend easl poster present long-term extens data wilson diseas
patient wilson therapeut acquir yesterday see note spent time discuss
differenti vs current approv standard care soc view data encourag demonstr
durabl maintain normal copper level improv disabl neurolog symptom
howev unmet medic need market size remain key question given use valeant vrx syprin
cuprimin standard care mainten copper chelat therapi enabl patient achiev control copper
level blood regard physician poster present easl note toler
complianc soc therapi remain major challeng critic given chronic chelat therapi
need attain excel long-term prognosi
tsro present initi data registration-en garnet studi msi-h endometri cancer nsclc
show orr pr confirm unconfirm msi-h endometri
cancer orr pr confirm unconfirm nsclc recurr set one
median prior line therapi
today fda approv opdivo/yervoy io combo rcc line today april pdufa date
opdivo/yervoy label restrict vs cabo rcc indic allow use across risk stratif
rcc despit opdivo/yervoy cabo cabosun trial enrol intermediate/poor-risk
intermediate/poor-risk rcc patient approv expect
label use
titl link note
liberti episod migrain data add aimovig
ema orphan de expect step toward
brazil surpris soliri ip break add
headwind soliri row rev
mackay takeaway nyc
ahead asgct mps-iiia updat
today market close announc top-lin result aimovig liberti studi episod migrain
patient fail prior therapi data compel support aimovig
cgrp class potenti especi hard-to-treat popul exhibit signific unmet need specif
aimovig top-lin result indic treat patient higher odd achiev reduct
number migrain day odd aimovig-tr vs placebo-tr patient achiev
migrain day reduct current model episod migrain larger driver peak ww sale
estim aimovig come address market
morn announc ema given orphan design od diseas
follow orphan pediatr diseas design alreadi grant fda view today
announc expect given rare incid preval yet posit showcas drive
rapidli bring novel gene therapi orphan debilit diseas clinic addit od provid
increas access feedback ema studi protocol assist see provid
potenti acceler path market od also provid reduc file fee market author
exclus await start develop guid start sale remain upsid model
afternoon media report cite brazilian govern broken soliri patent brazilian
attorney gener state countri abl produc biosimilar soliri break
brazilian latam sale note investor confer manag cite brazil compris
revenu would impli soliri sale come brazil though given
recent headwind rare diseas therapeut reimburs brazil note could even limit
kol see aimovig first-mov advantag enabl ownership migrain market ahu
market still rapidli grow increas diagnosi diseas secondari condit kol impress
data derm kol gave posit commentari dupix competit profil vs jak
reimburs though optho kol warn eylea inflamm effect concern lucenti pre-fil syring
could easier use optho kol spoke favor luxturna benefit caution us number
patient derm kol posit target caution read ad data singl site
uncontrol studi note rescu therapi allow trial could skew result kol spoke
favor adcetri hl see adcetri ad nccn guidelin becom soc
stage hl patient kol like patient extens diseas tki choic behind ipi nivo
like vegf io combo futur favor pure-play vegf io combo
rmat design increas contact fda await updat phase i/ii data patient
american societi gene cell therapi asgct may year
valid biosim herceptin
morn announc fda issu complet respons letter propos herceptin
biosimilar review eu chmp valid note fda focus addit
technic inform vs efficaci safeti issu nonetheless view posit herceptin
biosimilar current fda review pdufa action date may
titl link note
downgrad sp stop focu shift
decreas pt downgrad sp given discontinu lack near-term pipelin
catalyst upsid driver anticip stock rang bound trade cash multipl
manag determin cost-cut restructur strategi earli discoveri stage pipelin come focu
futur
quadra could add increment hrd tx market
focu remain oc maint oppti
morn tsro announc top-lin result zejula quadra studi treatment ovarian cancer
result brca platinum sensitive/resistant/refractori patient orr larg line lynparza studi
treatment experi orr quadra show interest zejula activ platinum sensit parpi-
naiv hrd patient orr though benefit non-brca hrd patient split remain
challeng interpret ahead full present
quick take surpris beat temper legaci
product larg drive win
see surpris beat top bottom line narrowing/up lower end revenu non-gaap ep
pt
surpris top bottom line beat temper legaci base busi product larg drive
revenu beat remain sector perform given threat base busi growth product launch gain
chang new gene therapi focu
bmrn top-lin bear driven one-tim account chang new pku gene therapi could reinvigor
violet blue gene therapi pku
quick take switch studi result read
expect come line
remain sector perform ahead upcom may pegvalias fda pdufa decis due risk/reward bake
model anticip continu invest gene therapi could rekindl investor interest
stock/stori ahead fall day today disclosur plan pku target gene therapi enter
